A suite of Griffith University research projects have received more than $5 million in research funding today from the National Health and Medical Research Council.
Griffith’s NHMRC outcomes for Investigator Grants, Partnership Projects (2018 PRC3) and Development Grants totalled $5,167,963.
“Warmest congratulations to the academic staff and their colleagues at other institutions who have achieved this success and many other staff within academic elements and central administration who have provided support,” Griffith Vice Chancellor and President, Professor Carolyn Evans said.
Dr Lauren Ball was awarded $1,526,912 for her Emerging Leadership Level 2 (EL2) Fellowship titled ‘Capitalising on the Potential of the Primary Care Setting to Facilitate Healthy Eating in the Australian Population’, that will be hosted by the Menzies Health Institute Queensland, Griffith Sciences.
Professor Michael Good was awarded $1,501,595 for his Leadership Level 3 (L3) Fellowship titled ‘Novel Vaccine Technology to Translate Knowledge of Immuno-Pathogenesis into Vaccines and Therapeutics’, that will be hosted by the Institute for Glycomics.
Associate Professor Dianne Shanley, Professor Melanie Gimmer-Zembeck, Professor Sheena Reilly, Professor Robert Ware, Associate Professor Joshua Byrnes, Professor Sharyn Rundle-Thiele and Professor Amanda Wheeler were awarded $1,070,761 for the project ‘A Tiered Approach to the Diagnosis of Fetal Alcohol Spectrum Disorder in Remote Indigenous Primary Care Settings’, that will be hosted by the Menzies Health Institute Queensland, Griffith Sciences.
Professor Suresh Mahalingam and Dr Adam Taylor were awarded $1,068,696 for the project: A New Vaccine to Protect Against Chikungunya Virus (and Similar Other Viruses) Causing Chronic Musculoskeletal Diseases’, that will be hosted by the Menzies Health Institute Queensland, Griffith Sciences.
Griffith University staff part of a team led by other institutions in a Development Grant
Professor Mark von Itzstein (Institute for Glycomics) for the project ‘Breaking Antibiotic Resistance in High Priority Gram-Negative Sepsis Pathogens’ (APP1176180), with Professor Mark Walker from the University of Queensland, $1,067,778.